Breast最新文献

{"title":"Prognostic factors and treatment insights for metastatic malignant phyllode tumors","authors":"Mengjia Han ,&nbsp;Yunyi Zhang ,&nbsp;Rong Lei ,&nbsp;Zijia Lai ,&nbsp;Zilin Zhuang ,&nbsp;Yulu Zhang ,&nbsp;Xun Li ,&nbsp;Xiaojun Li ,&nbsp;Rurong Jia ,&nbsp;Qiongchao Jiang ,&nbsp;Feng Ye ,&nbsp;Yan Nie","doi":"10.1016/j.breast.2025.104455","DOIUrl":"10.1016/j.breast.2025.104455","url":null,"abstract":"<div><h3>Background</h3><div>The aim of this study is to contribute a better understanding of metastatic malignant phyllode tumors (MMPTs) by exploring its prognostic factors, describing treatment landscape, and providing optimal treatment choices.</div></div><div><h3>Methods</h3><div>This retrospective multicentric study was included 43 patients with MMPTs who received treatment from 2009 to 2023 in four centers. The primary endpoint of the study was overall survival (OS).</div></div><div><h3>Results</h3><div>The median overall survival of these patients was 7.27 months (range: 0.63–118.53) and the median follow-up time was 16.8 months (range: 2–188). The median age of these patients were 49 years. The median metastasis-free survival (MFS, it is the time between initial diagnosis and diagnosis of metastatic disease) was 7.27 months, and the most common site of metastasis was lung (35/43, 81.4 %). Treatment for MMPTs primarily consisted of systemic chemotherapy and metastasectomy.</div><div>Multivariate analysis revealed that chemotherapy after metastasis (HR = 0.250, 95 % CI 0.109–0.571; <em>P</em> = 0.001) and MFS &gt;6 months (HR = 0.407, 95 % CI 0.198–0.836; P = 0.014) were independently associated with OS. The most common chemotherapy regimen was anthracyclines along with ifosfamide (AI), with the median progression-free survival of 5.5 months. Metastasectomy did not significantly improve OS.</div></div><div><h3>Conclusion</h3><div>The study findings highlight the significance of systemic treatment (chemotherapy) and the impact of MFS on prognosis of MMPTs. For these patients, systemic treatment may improve survival outcomes. And patients with MFS &lt;6 months appear to have a poorer prognosis.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104455"},"PeriodicalIF":5.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of surgical timing post-neoadjuvant chemotherapy on survival outcomes in breast cancer patients: A comprehensive systematic review and meta-analysis","authors":"Dandan Wang ,&nbsp;Xiaowei Sun ,&nbsp;Wen Sun ,&nbsp;Ruoxi Wang,&nbsp;Hong Pan,&nbsp;Wenbin Zhou","doi":"10.1016/j.breast.2025.104454","DOIUrl":"10.1016/j.breast.2025.104454","url":null,"abstract":"<div><h3>Background</h3><div>Increasing evidence supports the use of neoadjuvant chemotherapy (NAC) prior to surgery for breast cancer. However, the optimal timing between NAC and surgery had yet to be fully elucidated. This meta-analysis aims to assess how the optimal interval time (OTT) between NAC and surgery affects outcomes in breast cancer, providing additional evidence for clinical practice and future research.</div></div><div><h3>Methods</h3><div>PubMed<strong>,</strong> Web of Science and Cochrane Library databases in English were systematically searched for this systematic review. All included studies investigated the variations in surgical timing following NAC and their effects on breast cancer outcomes. The endpoints included the rate of pathological complete response (pCR), overall survival (OS), recurrence free survival (RFS), and disease-free survival (DFS). This study has been registered with PROSPERQ.</div></div><div><h3>Results</h3><div>Eleven eligible studies were identified, encompassing a total of 10,834 cases, all of which received surgery post-NAC. All studies were retrospective in nature. Ultimately, compared to intervals within 4 weeks, patients who underwent surgery&gt;8weeks post-NAC demonstrated a statistically significant worse OS (HR = 1.21, 95 % <em>CI</em>: 1.06–1.40, <em>p</em> = 0.333 for heterogeneity). No significant difference of OS was observed between patients with OTT of 4–8 weeks vs &lt; 4 weeks. Notably, patients with an OTT of 4–8 weeks (HR = 1.18, 95 % <em>CI</em>: 1.10–1.26, <em>I</em>^<em>2</em> = 0.0 %, p = 0.931 for heterogeneity) and&gt;8weeks (HR = 1.21, 95 % <em>CI</em>: 1.13–1.29, <em>I</em>^<em>2</em> = 36.2 %, <em>p</em> = 0.195 for heterogeneity) exhibited decreasing RFS, compared with those with OTTs of&lt;4 weeks. DFS and pCR rates were similar in&gt;8weeks vs &lt; 4 weeks and 4–8weeks vs &lt; 4 weeks.</div></div><div><h3>Conclusion</h3><div>Our systematic review and meta-analysis indicate that the optimal interval following NAC for breast cancer patients might be within four weeks, as delays exceeding eight weeks could be associated with poorer clinical outcomes. However, additional research is necessary to validate these preliminary findings.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104454"},"PeriodicalIF":5.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis","authors":"Rachel M. Layman ,&nbsp;Xianchen Liu ,&nbsp;Benjamin Li ,&nbsp;Lynn McRoy ,&nbsp;Adam Brufsky","doi":"10.1016/j.breast.2025.104448","DOIUrl":"10.1016/j.breast.2025.104448","url":null,"abstract":"<div><h3>Purpose</h3><div>To examine the associations of palbociclib dose modifications with clinical outcomes of patients with HR+/HER2− metastatic breast cancer (MBC) treated with first-line (1L) palbociclib + aromatase inhibitor (AI) in routine practice.</div></div><div><h3>Methods</h3><div>Using the Flatiron Health Analytic Database, we conducted a retrospective analysis of HR+/HER2− MBC patients who started 1L palbociclib + AI February 2015–March 2020. Kaplan−Meier analyses were used to estimate treatment duration, real-world progression-free survival (rwPFS), and overall survival (OS) by palbociclib dose adjustments (any change in palbociclib daily dose while on treatment) and dose reductions (starting dose &lt;125 mg/day or dose reduced while on treatment). Cox proportional hazard regression models were performed to compute unadjusted/adjusted hazard ratios (HRs).</div></div><div><h3>Results</h3><div>Of 1302 patients with documented starting dose, 524 (40.2 %) had palbociclib dose adjustments; 778 (59.8 %) had none. Median treatment duration was significantly longer in patients with dose adjustments versus those with none (27.4 vs 21.4 months; adjusted HR = 0.80 [95 % CI, 0.69–0.93]; <em>P</em> = 0.004). Patients with and without dose adjustments showed similar median rwPFS (20.5 vs 19.6 months; adjusted HR = 0.89 [95 % CI, 0.76–1.04]; <em>P</em> = 0.133). Median OS was significantly prolonged in patients with versus without dose adjustments (57.8 vs 51.4 months; adjusted HR = 0.73 [95 % CI, 0.59–0.89]; <em>P</em> = 0.002). Similar findings were observed in patients with and without dose reductions.</div></div><div><h3>Conclusions</h3><div>In this real-world study, rwPFS in HR+/HER2− MBC patients was maintained irrespective of dose adjustments. However, dose adjustments were associated with extended treatment duration and OS.</div></div><div><h3>Clinical trial registration</h3><div><span><span>NCT05361655</span><svg><path></path></svg></span> (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104448"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143695963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of oncological outcomes of premenopausal with ovarian function suppression versus postmenopausal women in ER+/HER2- breast cancer","authors":"Min Jung Lee ,&nbsp;Ji-Jung Jung ,&nbsp;Jong-Ho Cheun ,&nbsp;Eunhye Kang ,&nbsp;Hong-Kyu Kim ,&nbsp;Han-Byoel Lee ,&nbsp;Hyeong-Gon Moon ,&nbsp;Wonshik Han","doi":"10.1016/j.breast.2025.104449","DOIUrl":"10.1016/j.breast.2025.104449","url":null,"abstract":"<div><h3>Background</h3><div>The Rx for positive node endocrine-responsive breast cancer trial highlighted that premenopausal (PRE) women who underwent chemotherapy exhibited superior survival rates compared to postmenopausal (POST) counterparts, but showed worse survival without chemotherapy. This raises the question whether application of ovarian function suppression (OFS) in PRE women aligns with their cancer biology, treatment response, and outcomes observed in POST women.</div></div><div><h3>Methods</h3><div>Data from the Seoul National University Hospital breast cancer cohort focusing on patients with stage pT1-3, pN0-1, estrogen receptor-positive (ER+), and HER2-negative breast cancer were analyzed. Survival outcomes, including invasive disease-free survival (iDFS) and distant relapse-free survival (DRFS), were compared between PRE women receiving OFS and POST women, with chemotherapy usage as a stratification factor. Propensity score matching was performed.</div></div><div><h3>Result</h3><div>We analyzed 3483 patients, comprising 2901 POST and 582 PRE women with OFS. In the cohort without chemotherapy, the 10-year iDFS rates were 90.3 % and 88.3 % (hazard ratio [HR], 1.32; p = 0.16), and 10-year DRFS rates were 94.3 % and 96.1 % (HR, 0.78; p = 0.41) for POST and PRE women with OFS, respectively. Among women treated with chemotherapy, 10-year iDFS rates were 83.0 % and 79.5 % (HR, 1.21; p = 0.37), and DRFS rates were 86.7 % and 85.7 % (HR, 1.14; p = 0.58) for POST and PRE women with OFS, respectively. These results remained consistent after PSM.</div></div><div><h3>Conclusion</h3><div>Oncological outcomes of PRE women receiving OFS were comparable to those of POST women with ER+ and HER2-early breast cancer, irrespective of chemotherapy administration.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104449"},"PeriodicalIF":5.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial” [The Breast 78 (2004) 103795]","authors":"Karolina Larsson F ,&nbsp;Jamila Adra ,&nbsp;Leif Klint ,&nbsp;Barbro Linderholm","doi":"10.1016/j.breast.2025.104420","DOIUrl":"10.1016/j.breast.2025.104420","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104420"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Antibody-Drug conjugates in elderly patients with breast cancer” [The Breast 80 (2025) 104428]","authors":"Marta Bonotto ,&nbsp;Giulia De Pieri ,&nbsp;Rocco Esposto ,&nbsp;Ludovica Lay ,&nbsp;Silvia Buriolla ,&nbsp;Giuseppe Aprile ,&nbsp;Fabio Puglisi ,&nbsp;Alessandro Marco Minisini","doi":"10.1016/j.breast.2025.104440","DOIUrl":"10.1016/j.breast.2025.104440","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104440"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China","authors":"Yi Kuang ,&nbsp;Jiajia Qiu ,&nbsp;Ye Liu ,&nbsp;Sijin Guo ,&nbsp;Ting Chen ,&nbsp;Lichen Tang ,&nbsp;Winnie K.W. So ,&nbsp;Weijie Xing","doi":"10.1016/j.breast.2025.104441","DOIUrl":"10.1016/j.breast.2025.104441","url":null,"abstract":"<div><h3>Background</h3><div>Patients with breast cancer experience varying levels of financial toxicity (FT), but the factors contributing to sustained financial toxicity remain poorly understood.</div></div><div><h3>Methods</h3><div>This longitudinal study was conducted from November 2022 to March 2024 in China. Participants were recruited from four Tertiary Level A hospitals using convenient sampling. FT was assessed using the Comprehensive Score for Financial Toxicity (COST) at baseline (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Growth Mixture Modeling was used to identify the different trajectories of the FT. Multivariable logistic regression were employed to explore the predictive factors with different trajectory categories.</div></div><div><h3>Results</h3><div>Among 378 participants (all women; median [SD] age, 48.9 [9.97] years), the COST score was lowest at T2. Three distinct FT trajectories were identified: 91 patients <strong>(24 %)</strong> in the \"Severe FT with Gradual Relief\" group (trajectory 1), 190 patients <strong>(50 %)</strong> in the \"Persistently Low-Level FT\" group (trajectory 2), and 97 patients <strong>(</strong>26 %<strong>)</strong> in the \"Moderate FT with Gradual Worsening\" group (trajectory 3). Using trajectory 2 as the reference, predictors for trajectory 1 included symptom burden, location, cancer stage, cost-related health literacy, resilience, and difficulty affording basic expenses. For trajectory 3, predictors included monthly household income, symptom burden, location, and cancer stage.</div></div><div><h3>Conclusions</h3><div>The FT experienced by breast cancer patients changes over time and follows distinct dynamic trajectories, influenced by multiple factors. In future clinical practice, early identification and intervention for high-risk FT groups should be prioritized.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104441"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying germline pathogenic variants in breast cancer using tumor sequencing","authors":"Mara Cruellas ,&nbsp;Andri Papakonstantinou ,&nbsp;Adrià López-Fernández ,&nbsp;Ester Castillo ,&nbsp;Judit Matito ,&nbsp;Marina Gómez ,&nbsp;Alejandra Rezqallah ,&nbsp;Sharela Vega ,&nbsp;Víctor Navarro ,&nbsp;Maite Torres ,&nbsp;Alejandro Moles-Fernández ,&nbsp;Cristina Saura ,&nbsp;Ana Vivancos ,&nbsp;Judith Balmaña ,&nbsp;Mafalda Oliveira","doi":"10.1016/j.breast.2025.104439","DOIUrl":"10.1016/j.breast.2025.104439","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the performance of an in-house tumor sequencing panel to identify patients with breast cancer and a germline pathogenic variant (gPV).</div></div><div><h3>Patients and methods</h3><div>Retrospective and blinded tumor sequencing analysis in 90 patients with breast cancer and prior germline genetic testing (45 non-carriers and 45 carriers of a gPV) using an in-house panel (VHIO-300). Sensitivity (S), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) of tumor sequencing were calculated. A Cohen's kappa coefficient ≥0.80 was predefined as minimum to be reliably acceptable for clinical implementation.</div></div><div><h3>Results</h3><div>The cohort included 84 women and 6 men with a median age of 48 years (29–84). Tumors of germline carriers were mainly stage II (47 % vs 31 %, P = 0.047), luminal B-like (56 % vs 31 %, p = 0.037) or triple negative (22 % vs 16 %, = 0.037). The in-house tumor panel identified 91 % (40/44) of the gPV. The analysis did not detect any of the 2 patients with germline large rearrangement alterations nor 2 of the 7 patients with intronic variants included. The tumor sequencing panel yielded 7 % of false positive results (ie, genetic alterations suggestive of germline origin). Hence, S was 91 %, Sp 93 % and Cohen's kappa coefficient between tumor and germline testing was 0.84 (95 % CI 0.73–0.95).</div></div><div><h3>Conclusion</h3><div>Tumor tissue sequencing with our in-house panel demonstrated an acceptable performance to identify patients with breast cancer carriers of a gPV.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104439"},"PeriodicalIF":5.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prediction of cardiovascular events following treatments in female breast cancer patients: Application of real-world data and artificial intelligence","authors":"Quynh T.N. Nguyen ,&nbsp;Shwu-Jiuan Lin ,&nbsp;Phung-Anh Nguyen ,&nbsp;Phan Thanh Phuc ,&nbsp;Min-Huei Hsu ,&nbsp;Chun-Yao Huang ,&nbsp;Chin-Sheng Hung ,&nbsp;Christine Y. Lu ,&nbsp;Jason C. Hsu","doi":"10.1016/j.breast.2025.104438","DOIUrl":"10.1016/j.breast.2025.104438","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104438"},"PeriodicalIF":5.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143703956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer","authors":"Joyce O'Shaughnessy ,&nbsp;Sara M. Tolaney ,&nbsp;Denise A. Yardley ,&nbsp;Lowell Hart ,&nbsp;Pedram Razavi ,&nbsp;Peter A. Fasching ,&nbsp;Wolfgang Janni ,&nbsp;Lee Schwartzberg ,&nbsp;Julia Kim ,&nbsp;Murat Akdere ,&nbsp;Courtney McDermott ,&nbsp;Aamir Khakwani ,&nbsp;Purnima Pathak ,&nbsp;Stephanie L. Graff","doi":"10.1016/j.breast.2025.104437","DOIUrl":"10.1016/j.breast.2025.104437","url":null,"abstract":"<div><h3>Background</h3><div>Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/HER2- EBC treated with adjuvant ET.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted using the ConcertAI Patient360 database (January 1995 to April 2021) of patients with stage II/III HR+/HER2- EBC ≥18 years who underwent surgery and received adjuvant ET. Risk of recurrence was assessed using invasive disease-free survival (iDFS) with adapted STEEP criteria. An ET subanalysis evaluated iDFS, distant disease-free survival, and overall survival in patients receiving adjuvant non-steroidal aromatase inhibitors (NSAI) vs tamoxifen.</div></div><div><h3>Results</h3><div>In the full analysis cohort (N = 3133), the risk of an iDFS event was 26.1 % at 5 years, rising to 45.0 % at 10 years. Among patients with stage II disease, the risk of an iDFS event at 5 and 10 years was 22.7 % and 40.5 %, respectively; stage III 5- and 10-year risk was 40.4 % and 62.9 %. Patients with node-negative disease had 5- and 10-year risks of 22.1 % and 36.9 %, respectively; node-positive 5- and 10-year risk was 28.9 % and 49.4 %. ET subanalysis showed improved iDFS with NSAI ± ovarian function suppression vs tamoxifen ± ovarian function suppression (HR, 0.83; 95 % CI, 0.69–0.98; p = 0.031); this trend was observed regardless of menopausal status.</div></div><div><h3>Conclusions</h3><div>This real-world study highlights the considerable risk of recurrence with adjuvant ET in patients with stage II or III HR+/HER2- EBC (including node-negative disease) and confirms the need for improved treatment options.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104437"},"PeriodicalIF":5.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}